« Previous | Next » | All Messages |  MDSC Message Board Home | recommend post |  Ignore Poster

MDSC News Mediscience Technology Corp. and Infotonics Technology Center Inc. Report ''Compact Photonic Explorer'' (CPE), ''Pill Camera'' Progress

The parties announced their agreement to jointly develop the Compact Photonic Explorer (CPE), or pill camera, on September 8, 2004 The initial focus of the project --developing a (CPE) " that would detect cancer and monitor body functions". The goal - to create an ingestible photonic pill that would enable physicians to detect early stage cancer of the complete auto-digestive tract. Such a non-invasive device would lead to reduced mortality and health care costs, and would significantly increase the number of people who could be screened for this type of cancer.

The proof-of-concept research for the (CPE), led by Dr. Robert Alfano and his team at City University of New York (CUNY), has been successful based upon an on-going four-year multidisciplinary/multi-institutional effort to develop miniature devices that use light to remotely monitor the health of various environments in collaboration with researchers at Cornell, SUNY Albany, SUNY Binghamton, RPI, Rochester Institute of Technology, the University of Rochester, and Boston University."

(Infotonics) is a consortium whose founding participants include Corning, Inc., Eastman Kodak Company, and Xerox Corporation, a not-for-profit corporation that operates New York State's Center of Excellence in Photonics and Microsystems.

(MTC) Chairman/CEO Peter Katevatis stated "this joint effort between Medi-photonics and Infotonics is a synergistic and strategic fit leveraging the Center's unique nano-technology capabilities, resources and (MTC) optical biopsy IP. This project has enhanced (MTC) proprietary non-invasive imaging "optical biopsy" technology for molecular detection of cancer and physiological change and the Company's desire to commercialize its patented technology."

David R. Smith President & CEO (Infotonics) states "Capital investment would be required to establish the pilot production capability (e.g initial units for FDA clinicals) and the amount of capital funds would vary greatly with the production capacity required. From an R&D perspective we would proceed/participate in presentations etc together to seek competitive grant funding from NIH, and other available sources public and/or private. With our assistance and support Medi-Photonics LLC/Mediscience would at some early juncture contact/meet with the Empire State Development agency and Ontario County in New York State who have from project inception expressed significant New York State economic interest in the Rochester New York State area with significant financial incentives for the Compact Photonics Explorer (CPE) project should the project locate here. Infotonics is committed to support the appropriate path forward for Medi-Photonics LLC/Mediscience business success."

About the Infotonics Center

(Infotonics) is a not-for-profit corporation that operates New York State's Center of Excellence in Photonics and Microsystems. Infotonics is structured as a consortium whose founding participants include Corning, Inc., Eastman Kodak Company, and Xerox Corporation. The Rochester Regional Photonics Cluster is an industrial partner, and academic participants include some 20 New York State colleges and universities. Infotonics' goal is to establish a unique, world-class research and development facility to enable rapid commercialization of new products. This initiative will provide major benefits to the region, including creation of jobs and attraction of new companies and investment revenue.

About Mediscience Technology

Mediscience Technology Corporation and its New York subsidiary, Medi-photonics Development Company LLC, is engaged in the design, development and commercialization of medical devices that detect cancer and physiological change using frequencies of light that are emitted, scattered and absorbed to distinguish malignant, precancerous, or benign tissues from normal tissues. Mediscience's exclusive protected IP noninvasive technology combines the advantages of real-time results with enhanced diagnostic sensitivity and specificity compared with other methods of cancer detection.

See Web sites:

http://www.infotonics.org/ResearchProjects/ CompactPhotonicExplorers.asp (Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field.)

www.cunyphotonics.com

MEDISCIENCETECH.com

See Mediscience 8-K filing dated September 8, 2004

See New England Journal of Medicine 7-29-04 (general results of developing capsule endoscopic technology)

CITIGROUP/Smith Barney Analyst Report 10-1-2004 by Peter Bye. Page 20 (GIVEN IMAGING-Mediscience/Infotonics)

INVESTOR NOTICE:

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the parties/ company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the parties/ company's ability to implement its long-range business plan for various applications of its technology; including but not limited to that expressed herein; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances applicable to applications of the company' technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the parties/ company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G.